TELA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TELA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
TELA Bio's operating assets for the quarter that ended in Dec. 2023 was $31.32 Mil. TELA Bio's operating liabilities for the quarter that ended in Dec. 2023 was $18.09 Mil. TELA Bio's Total Assets for the quarter that ended in Sep. 2023 was $87.32 Mil. Therefore, TELA Bio's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was 0.15.
The historical data trend for TELA Bio's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TELA Bio Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Scaled Net Operating Assets | Get a 7-Day Free Trial | 0.24 | 0.08 | 0.09 | 0.20 | 0.20 |
TELA Bio Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Scaled Net Operating Assets | Get a 7-Day Free Trial | 0.16 | 0.20 | 0.26 | 0.14 | 0.15 |
For the Medical Devices subindustry, TELA Bio's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, TELA Bio's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where TELA Bio's Scaled Net Operating Assets falls into.
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
TELA Bio's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as
Scaled Net Operating Assets (SNOA) | (A: Dec. 2023 ) | ||||
= | (Operating Assets (A: Dec. 2023 ) | - | Operating Liabilities (A: Dec. 2023 )) | / | Total Assets (A: Dec. 2022 ) |
= | (31.319 | - | 18.087) | / | 67.855 |
= | 0.20 |
where
Operating Assets | (A: Dec. 2023 ) | ||
= | Total Assets | - | Cash, Cash Equivalents, Marketable Securities |
= | 78.048 | - | 46.729 |
= | 31.319 |
Operating Liabilities | (A: Dec. 2023 ) | ||||
= | Total Liabilities | - | Long-Term Debt & Capital Lease Obligation | - | Short-Term Debt & Capital Lease Obligation |
= | 59.167 | - | 40.515 | - | 0.565 |
= | 18.087 |
TELA Bio's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as
Scaled Net Operating Assets (SNOA) | (Q: Dec. 2023 ) | ||||
= | (Operating Assets (Q: Dec. 2023 ) | - | Operating Liabilities (Q: Dec. 2023 )) | / | Total Assets (Q: Sep. 2023 ) |
= | (31.319 | - | 18.087) | / | 87.317 |
= | 0.15 |
where
Operating Assets | (Q: Dec. 2023 ) | ||
= | Total Assets | - | Cash, Cash Equivalents, Marketable Securities |
= | 78.048 | - | 46.729 |
= | 31.319 |
Operating Liabilities | (Q: Dec. 2023 ) | ||||
= | Total Liabilities | - | Long-Term Debt & Capital Lease Obligation | - | Short-Term Debt & Capital Lease Obligation |
= | 59.167 | - | 40.515 | - | 0.565 |
= | 18.087 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of TELA Bio's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Gregory A. Firestone | officer: Chief Business Officer | C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355 |
Roberto Cuca | officer: COO and CFO | C/O TREVENA, INC., 1018 WEST 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406 |
Antony Koblish | director, officer: Chief Executive Officer | C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355 |
Orbimed Advisors Llc | 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Orbimed Capital Gp Iv Llc | 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Opaleye Management Inc. | 10 percent owner | ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108 |
Ew Healthcare Partners Fund 2-a, L.p. | other: See footnotes 1 and 2 | 280 PARK AVENUE, 27TH FLOOR EAST, NEW YORK NY 10017 |
Quaker Bioventures Ii Lp | 10 percent owner | QUAKER BIOVENTURES, 2929 ARCH STREET, PHILADELPHIA PA 19104 |
Quaker Bioventures Capital Ii, L.p. | 10 percent owner | CIRA CENTER, 2929 ARCH STREET, PHILADELPHIA PA 19104 |
Lisa N Colleran | director | 0NE MILLENIUM WAY, BRANCHBURG NJ 08876 |
John Nosenzo | director | C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703 |
Federica F. O'brien | director | C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355 |
Kurt Azarbarzin | director | C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355 |
Vincent J Burgess | director | 2210 FARADAY AVE #100, CARLSBAD CA 92008 |
Douglas G Evans | director | 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355 |
From GuruFocus
By Marketwired • 08-04-2023
By sperokesalga sperokesalga • 05-08-2023
By GlobeNewswire GlobeNewswire • 04-19-2023
By Stock market mentor Stock market mentor • 01-20-2023
By sperokesalga sperokesalga • 05-19-2023
By Stock market mentor Stock market mentor • 01-09-2023
By sperokesalga sperokesalga • 02-28-2023
By sperokesalga sperokesalga • 03-29-2023
By Marketwired • 08-16-2023
By GuruFocus Research GuruFocus Editor • 01-13-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.